Global Epinephrine Market Segments 2024, Forecast To 2033
5 Mar, 2024
The epinephrine market has rapidly expanded, growing from $2.44 billion in 2023 to $2.69 billion in 2024 with a 10.4% CAGR. The surge is attributed to factors like anaphylaxis incidence, regulatory framework, increased allergies, patient education, and improved accessibility. Looking ahead, strong growth is anticipated, reaching $3.82 billion in 2028 at a 9.2% CAGR. The forecasted expansion is fueled by rising allergy rates, expanded access initiatives, awareness campaigns, emerging markets, and customized epinephrine delivery systems. Notable trends include the integration of smart devices, enhanced education and awareness programs, global expansion of epinephrine access, and collaborative research and development efforts.
Global Epinephrine Market Key Driver
The epinephrine market sees growth amid the increasing prevalence of chronic respiratory diseases, including asthma and COPD. The World Health Organization reported 41 million deaths from chronic diseases in 2023. As respiratory diseases rise due to factors like air pollution, the demand for epinephrine, crucial for severe asthma attacks, is set to increase, reflecting the market's response to the escalating health challenges.
Get A Free Sample Of The Global Epinephrine Market ReportGlobal Epinephrine Market Segments
The epinephrine market covered in this report is segmented –
1) By Type: Prefilled Syringe, Auto-injector, Ampoules and Vials
2) By Application: Anaphylaxis, Cardiac Arrest, Superficial Bleeding, Respiratory Disorders, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the epinephrine market in 2023. The regions covered in the epinephrine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Epinephrine Industry Players
ALK-Abelló A/S; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan NV; Amneal Pharmaceuticals Inc.; Bausch Health Companies Inc.; Abbott Laboratories; Sanofi SA; Viatris Inc.; Lincoln Medical Ltd.; Kaleo Inc.; Gland Pharma Limited; Adamis Pharmaceuticals Corporation; Harvest Pharmaceuticals Inc.; Merit Pharmaceutical; Hospira, Inc.; Antares Pharma Inc.; Bausch & Lomb Incorporated; Novartis AG; Grand Pharma (China) Co. Ltd.; Impax Laboratories LLC; Sandoz International GmbH; Tianjin Jinyao Group Co. Ltd.; GlaxoSmithKline plc; Amphastar Pharmaceuticals Inc.; Par Sterile Products LLC; Amedra Pharmaceuticals LLC; Crossject SA; Halozyme Therapeutics Inc
Get The Full Global Epinephrine Market Report
AIOps Epinephrine Market Overview
Epinephrine, also known as adrenaline, is a hormone and neurotransmitter used for life-threatening allergic reaction treatment spurred by foods, medicines, latex, insect bites or stings, and other reactions treated with epinephrine injections along with emergency medical treatment.
Epinephrine Global Market Report 2023 provides data on the global epinephrine market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The epinephrine market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.